Agile Therapeutics (AGRX) PT Lowered to $5 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts AGRX Hot Sheet
Price: $1.51 --0%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
RBC Capital analyst Daniel Busb lowered the price target on Agile Therapeutics (NASDAQ: AGRX) to $5.00 (from $6.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Datadog (DDOG) PT Lowered to $275 at TD Cowen
- Snap Inc (SNAP) PT Raised to $5.75 at DA Davidson
- Fastly Inc. (FSLY) PT Lowered to $17 at DA Davidson
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
